Isotretinoin
- Generic Name
- Isotretinoin
- Brand Names
- Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 4759-48-2
- Unique Ingredient Identifier
- EH28UP18IF
- Background
Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-cont...
- Indication
Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.
- Associated Conditions
- Acne conglobata, Neuroblastoma (NB), Rosacea, Sezary Syndrome, Early Mycosis Fungoides (MF), Refractory Acne vulgaris, Severe Recalcitrant nodular acne
- Associated Therapies
- -
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT01560585
- Locations
- 🇺🇸
Parkway Medical Building, Beachwood, Ohio, United States
Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne
- Conditions
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 266
- Registration Number
- NCT01474590
- Locations
- 🇨🇦
Galderma investigational site, Woodbridge, Canada
Isotretinoin for Proliferative Vitreoretinopathy
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Wills Eye
- Target Recruit Count
- 109
- Registration Number
- NCT01445028
- Locations
- 🇺🇸
Wills Eye Institute, Philadelphia, Pennsylvania, United States
A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2011-07-27
- Lead Sponsor
- University of Aberdeen
- Target Recruit Count
- 18
- Registration Number
- NCT01404130
- Locations
- 🇬🇧
Anthony Ormerod, Aberdeen, Aberdeenshire, United Kingdom
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 52
- Registration Number
- NCT01334515
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States
🇺🇸Natalie W Bryant Cancer Center, Tulsa, Oklahoma, United States
Aflac ST1001 Prolonged Isotretinoin
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- Emory University
- Registration Number
- NCT01319838
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT01208454
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
- Conditions
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CisplatinDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: Etoposide PhosphateRadiation: External Beam Radiation TherapyProcedure: In Vitro-Treated Peripheral Blood Stem Cell TransplantationRadiation: Intensity-Modulated Radiation TherapyRadiation: Iobenguane I-131Drug: IsotretinoinOther: Laboratory Biomarker AnalysisDrug: MelphalanOther: Pharmacological StudyOther: Questionnaire AdministrationProcedure: Therapeutic Conventional SurgeryDrug: Topotecan HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 99
- Registration Number
- NCT01175356
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
- Conditions
- Interventions
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 5
- Registration Number
- NCT01103375
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
- First Posted Date
- 2010-01-01
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 105
- Registration Number
- NCT01041638
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.